Navigation Links
CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
Date:8/25/2009

PALO ALTO, Calif., Aug. 25 /PRNewswire/ -- CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.

Following completion of the validation study, CardioDx has made Corus CAD available in nine states initially, with broader availability expected in 2010. The test is now available in Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient samples are processed in Palo Alto at CardioDx's CLIA-certified laboratory.

"Completing the validation study for Corus CAD marks a major milestone for CardioDx," said David Levison, chief executive officer of CardioDx. "Our focus now turns to further developing the clinical and economic evidence needed to increase patient access to the unique benefits of Corus CAD."

Currently, the presence of obstructive CAD in patients with stable chest pain is most often evaluated through functional and/or anatomical assessment of the heart and its vessels, including stress echocardiography, myocardial perfusion imaging, and computed tomography angiography. However, despite advances in imaging technology, these techniques can be subjective and challenging for cardiologists, because of variation in presenting symptoms and each patient's unique disease characteristics. Corus CAD provides unique genomic information about an individual's disease processes at the molecular and cellular levels. When this information is combined with standard clinical assessments, physicians obtain a more complete picture of their patient's disease and can bett
'/>"/>

SOURCE CardioDx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/56cq5n/motion_simulation ) has ... Market by Type (Hydraulic and Actuator), Degree of ... Application (Automotive, Defense, Entertainment, Healthcare, Mining, R&D, Sports, ... " report to their offering. ... enough for commercial use, and thus its market ...
(Date:6/2/2015)...  Nektar Therapeutics (NASDAQ: NKTR ) and The ... a research collaboration that includes a Phase 1/2 clinical ... preferentially stimulate production of CD8-positive T cells, which are ... which is also known as the Interleukin-2 receptor beta ... to increase proliferation of these effector T cells. 1 ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
Breaking Medicine Technology:Global Motion Simulation Market 2015-2020 - Type, Degree of Freedom, Application, and Regional Analysis 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2
... Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a ... company will actively participate at the Save A Leg, ... in Orlando tomorrow, October 8. , In addition to exhibiting its ... a workshop entitled " The ...
... ACCESS PHARMACEUTICALS, INC . (OTC ... agreement with iMedicor (OTC Bulletin Board: VMCI) for the North ... rinse for the management of oral mucositis and stomatitis caused ... System application, initial introduction of MuGard to the 216,000 selected ...
Cached Medicine Technology:Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 2Wound Management to Participate at Save A Leg, Save a Life Foundation National Conference 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 2Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 3Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM) 4
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity ... summer fashion cocktail dresses. The company carries more than ... be suitable for a wide variety of summer events ... and make high quality trendy special occasion dresses ... quality satin, chiffon and cotton. Their products feature a ...
(Date:6/2/2015)... 2015 Consumer Reports, the world’s ... announced its commitment to help wipe out antibiotic-resistant ... of antibiotics sicken about 2.25 million Americans each ... for Disease Control and Prevention. , The initiative ... Marta Tellado participating in the White House Forum ...
(Date:6/2/2015)... 2015 Amercanex, the American Cannabis ... to become Amercanex’s new Chief Technology Officer. Amercanex ... which cultivators, wholesale distributors and retail vendors can ... fully transparent intra-state market. , Jim Miller is ... technology space, helping innovative technology companies deliver on ...
(Date:6/2/2015)... Colleen’s Dream Foundation , with fundraising help from ... to support ovarian cancer research conducted by Cheng Wang, Ph.D. ... Colleen’s Dream Foundation Board of Directors. , Cundiff says the ... Colleen’s Dream Foundation and they couldn’t have picked a better ... a rising star in the ovarian cancer world,” says Cundiff. ...
(Date:6/2/2015)... 2015 Each year, Cosmetic Executive Women ... Awards. This year, the organization’s members – 8,000 industry ... the QVC® Beauty Quest Award at the 2015 Beauty ... (ME) Technology and 2-in-1 approach to skincare differentiated it ... brand’s loyal consumer and professional fan bases, QVC has ...
Breaking Medicine News(10 mins):Health News:Consumer Reports Aims to Stop the Spread of Superbugs 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 3Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2
... 22 Atlas Spine, Inc., a spinal,technology development ... announced today the national launch of the STATURE ... radiolucent MIS compatible spacer,system designed to utilize a ... the thoracic and lumbar spine., "After significant ...
... Its Summer-Long Harley-Davidson ... Celebration Promotion, MILWAUKEE, May 22 Miller Brewing Company ... every Miller Lite,bottle cap collected now through Sept. 1, 2008, ... the "ultimate light beer,",is the official beer sponsor of this ...
... The Foundation of the National Student Nurses Association ... Jersey Regional Faculty Fellowships to two Rutgers College of ... The fellowship will help Ho-Shing, a Union, N.J. resident, ... academic fees, and book expenses during the Fall 2008 ...
... Providing Real Parental Reassurance, NEW YORK, May ... developer of biosensor and microprocessor technologies for,use in ... trials for its latest homecare wellness product using ... the traditional home baby,monitor market., Each year, ...
... $4 MILLION INVESTMENT WILL SUPPORT AMERICA,S NEW GENERATION ... The National,Alliance for Hispanic Health (the Alliance) announced ... a new,partnership improving Hispanic student access to higher ... (STEM). The Program is,made possible through a $4 ...
... Global Reach of Novel Technology, N. BILLERICA, ... measurement of cellular bioenergetics, announced today,that Primetech Corporation ... and consumables in Japan., "Japan,s contribution to ... we have seen with the recent acquisition of ...
Cached Medicine News:Health News:Atlas Spine Launches Stature(TM) Vertebral Body Replacement System 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 3Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2
... C spins up to 25,000 x g for quick ... and ease of use. The Model 5417 C is ... a cold room and can accommodate a variety of ... , Spin up to 16,400 rpm; 25,000 x ...
... laboratory floor model centrifuge meets UL and ... suitable for use in Class 1, Group ... gasoline, petroleum, naphtha, benzol, lacquer, solvent vapors ... is so strict that the EXD design ...
... Hybridization Oven/Shaker rigidly controls the temperature ... of hybridization and washing steps. This ... of nucleic acids and proteins immobilized ... with radioactive and nonradioactive labeling systems ...
... Oven with circular clear acrylic chamber for ... HybriCycler Oven features microprocessor operation for precise ... the unit., Carousel rotates at 11 ... ,easily removable , Bottle Capacity - ...
Medicine Products: